A Combined CRISP3 and SPINK1 Prognostic Grade in EPS-Urine and Establishment of Models to Predict Prognosis of Patients With Prostate Cancer

Frontiers in Medicine

article

Lizhu Chen¹  Enchong Zhang²  Johnny Guan³  Zhengjie Chen²  Jianfeng Ye²  Wangmin Liu²  Jieqian He²  Bo Yin²  Yongsheng Song²  Mo Zhang² 

[1] Department of Ultrasound, Shengjing Hospital of China Medical University;Department of Urology, Shengjing Hospital of China Medical University;Department of Urology, David Geffen School of Medicine, University of California

关键词: CRISP3;    SPINK1;    biomarker;    EPS-urine;    prognostic model;   

DOI  :  10.3389/fmed.2022.832415

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background Prostate cancer (PCa) is characterized by significant heterogeneity. Thus, novel prognostic indicators are required to improve prognosis and treatment. Methods Cysteine rich secretory protein 3 (CRISP3) and serine peptidase inhibitor Kazal type 1 (SPINK1) levels in expressed prostatic secretion (EPS)-urine collected during digital rectal examination of 496 patients histologically diagnosed with PCa were detected via enzyme-linked immunosorbent assay. A combined CRISP3 and SPINK1 prognostic grade (CSPG) was defined using cut-off values from receiver operating characteristic curves. Log-rank Kaplan-Meier survival curves investigated differences in prognosis between groups. Univariate and multivariate Cox analyses investigated the CSPG relationship with biochemical recurrence (BCR), cancer-specific survival (CSS), and overall survival (OS). Three prognostic models were developed and validated. Conclusions CRISP3 and SPINK1 levels increased with Gleason score progression, pathological T stage, and metastasis status. CSPG in EPS-urine, which was an effective independent prognostic variable, accurately predicted the prognosis of patients with PCa. Three clinical prognostic models using the CSPG for BCR, CSS, and OS were developed and validated.

【 授权许可】

CC BY